General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Theratechnologies Inc.
Indication:
As an adjunct to diet for the treatment of adults with familial chylomicronemia syndrome (FCS) to reduce triglyceride levels.
Last updated July 4, 2026
Alyftrek (vanzacaftor, tezacaftor, deutivacaftor)
Status:
Concluded with an LOI
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Indication:
Cystic fibrosis, F508del or responsive CFTR mutation, 6 years and older
Last updated July 3, 2026
Status:
Under consideration for negotiation
Manufacturer:
Biogen Canada Inc.
Indication:
Friedreich's ataxia
Last updated June 30, 2026
Enhertu (trastuzumab deruxtecan)
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Advanced or Metastatic Gastric Cancer or Gastro-esophageal Junction (GEJ) Adenocarcinoma
Last updated June 29, 2026
Enhertu (trastuzumab deruxtecan)
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
For the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting and are not considered suitable for endocrine therapy as the next line of treatment.
Last updated June 29, 2026
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Atopic dermatitis
Last updated June 26, 2026
Status:
Concluded with an LOI
Manufacturer:
Mirum Pharmaceuticals Inc.
Indication:
For the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients 3 months and older.
Last updated June 26, 2026
Status:
Active negotiation
Manufacturer:
Eisai Limited
Indication:
Insomnia
Last updated June 26, 2026
Status:
Concluded with an LOI
Manufacturer:
Valorum Biologics LLC
Indication:
Multiple Indications
Last updated June 25, 2026
Status:
Concluded with an LOI
Manufacturer:
CSL Behring Canada Inc.
Indication:
Hereditary Angioedema
Last updated June 25, 2026